The DBTL cycle does not complete without the T. Without rich datasets from scale-down fermentations in the 10s to 100s of mL scale, strain improvements languish in the realm of theory. They may be the casualties of noise overwhelming signal, or no vacancy in the bioreactor. Dr. Gian Oddone, in his 16-year career developing industrial bioprocesses for converting sugar to enzymes, chemicals, biopesticides, nutrients and therapeutics, knows the strain-overloaded testing problem well. At Biolucid LLC, Dr. Oddone helps clients develop their research platforms, tools, and bioprocess technologies, applying his metabolic engineering expertise, scientific rigor, and flexible automation/programming solutions to light a path to commercialization. Dr. Oddone has previously held bioprocess leadership roles at Genomatica (now Geno), Marrone Bio Innovations (now Profarm), and Novozymes (now Novonesis).

‍